Comparative Pharmacology
Head-to-head clinical analysis: DITATE DS versus H CORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DITATE DS versus H CORT.
DITATE-DS vs H-CORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DITATE-DS is a combination of dexamethasone, a corticosteroid with anti-inflammatory and immunosuppressant properties, and trimethoprim, a folate antagonist. Dexamethasone acts by binding to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response. Trimethoprim inhibits dihydrofolate reductase, blocking bacterial folate synthesis and exerting antibacterial effects.
H-CORT (hydrocortisone) is a corticosteroid with glucocorticoid and mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
1 tablet (0.5 mg dexamethasone/5 mg cyproheptadine) orally every 8 hours, maximum 3 tablets daily.
Intravenous: 100-250 mg as a single dose or up to 1 gram daily for acute conditions. Oral: 20-30 mg daily in divided doses. Maintenance: 5-20 mg daily.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Terminal elimination half-life: 1.5-2 hours. Clinical context: Short half-life requires q4-6h dosing; duration may be prolonged in hepatic impairment.
Renal (50-60% as unchanged drug and metabolites), biliary/fecal (40-50% as metabolites and unchanged drug).
Renal: ~80% as metabolites, ~5% unchanged; biliary/fecal: ~15%
Category C
Category C
Corticosteroid
Corticosteroid